TLX
Price
$9.54
Change
-$0.49 (-4.89%)
Updated
Oct 22 closing price
Capitalization
3.24B
Earnings call today
Intraday BUY SELL Signals
ZLAB
Price
$22.04
Change
-$2.16 (-8.93%)
Updated
Oct 22 closing price
Capitalization
2.47B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

TLX vs ZLAB

TLX vs ZLAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
TLX vs. ZLAB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TLX is a Hold and ZLAB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for TLX with price predictions
Oct 22, 2026

TLX sees MACD Histogram crosses below signal line

TLX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 21, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 17 instances where the indicator turned negative. In 16 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLX as a result. In 25 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

TLX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TLX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 6 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

The Aroon Indicator for TLX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +4.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLX advanced for three days, in 79 of 109 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

TLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. TLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.647) is normal, around the industry mean (2.973). TLX's P/E Ratio (96.657) is considerably higher than the industry average of (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.354) is also within normal values, averaging (438.009).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ZLAB with price predictions
Oct 22, 2026

ZLAB's RSI Indicator ascending out of oversold territory

The RSI Indicator for ZLAB moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 31 of the 37 cases the stock moved higher. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 59 cases where ZLAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +8.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in 201 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

ZLAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZLAB as a result. In 63 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

ZLAB moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ZLAB crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ZLAB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.076) is normal, around the industry mean (2.973). P/E Ratio (-12.965) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.079) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ZLAB: Fundamental Ratings
ZLAB
OUTLOOK RATING
1..100
68
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
51
P/E GROWTH RATING
1..100
50
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
TLXZLAB
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
81%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (TLX: $10.03 vs. ZLAB: $22.04)
Brand notoriety: TLX and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: TLX: 254% vs. ZLAB: 130%
Market capitalization -- TLX: $3.24B vs. ZLAB: $2.47B
TLX [@Biotechnology] is valued at $3.24B. ZLAB’s [@Biotechnology] market capitalization is $2.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TLX’s FA Score shows that 0 FA rating(s) are green while ZLAB’s FA Score has 1 green FA rating(s).

  • TLX’s FA Score: 0 green, 5 red.
  • ZLAB’s FA Score: 1 green, 4 red.
According to our system of comparison, ZLAB is a better buy in the long-term than TLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TLX’s TA Score shows that 3 TA indicator(s) are bullish while ZLAB’s TA Score has 4 bullish TA indicator(s).

  • TLX’s TA Score: 3 bullish, 6 bearish.
  • ZLAB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ZLAB is a better buy in the short-term than TLX.

Price Growth

TLX (@Biotechnology) experienced а -5.82% price change this week, while ZLAB (@Biotechnology) price change was -6.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

TLX is expected to report earnings on Oct 22, 2026.

ZLAB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
TLX
Daily Signal:
Gain/Loss:
ZLAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

TLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLX has been loosely correlated with GNPX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if TLX jumps, then GNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLX
1D Price
Change %
TLX100%
-4.89%
GNPX - TLX
35%
Loosely correlated
-3.41%
APVO - TLX
32%
Poorly correlated
+0.62%
ZLAB - TLX
28%
Poorly correlated
-8.93%
ABSI - TLX
27%
Poorly correlated
-6.67%
BMEA - TLX
27%
Poorly correlated
-15.23%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ORIC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-8.93%
ORIC - ZLAB
34%
Loosely correlated
-1.59%
AMRN - ZLAB
33%
Loosely correlated
+0.78%
ONC - ZLAB
33%
Poorly correlated
-1.08%
VCYT - ZLAB
32%
Poorly correlated
-0.39%
AXON - ZLAB
32%
Poorly correlated
+2.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JETU20.470.13
+0.63%
MAX Airlines 3X Leveraged ETNs (JETU)
SCSB24.640.06
+0.24%
Sterling Capital Short Duration Bond ETF (SCSB)
HERZ15.42N/A
N/A
Herzfeld Credit Income Fund Inc.
AIEQ49.09-0.55
-1.11%
Amplify AI Powered Equity ETF (AIEQ)
QDPL45.88-0.54
-1.16%
Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF (QDPL)